Is oxytocin a therapeutic factor for ischemic heart disease?
Related Experiment Video
Updated: May 11, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Ali Mohammad Alizadeh1, Parasto Mirzabeglo
1Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran. aalizadeh@razi.tums.ac.ir
Insights
Oxytocin shows promise as a cardioprotective agent for ischemic heart disease (IHD). This peptide may enhance myocardial function and reduce injury, offering new therapeutic avenues for IHD patients.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Research
Background:
- Ischemic heart disease (IHD) is a leading cause of mortality worldwide.
- Preventive and interventional strategies for IHD are under active investigation.
- Cardioprotective agents are crucial for improving outcomes in IHD.
Purpose of the Study:
- To review the potential cardioprotective effects of oxytocin in the context of IHD.
- To evaluate oxytocin's role in pharmacologic preconditioning and reducing reperfusion injury.
- To assess oxytocin's impact on myocardial function and infarction extent.
Main Methods:
- Literature review of experimental evidence on oxytocin and IHD.
- Analysis of studies investigating oxytocin's effects on myocardial injury and function.
- Synthesis of data regarding oxytocin's potential as a cardioprotective agent.
Main Results:
- Experimental evidence suggests oxytocin possesses cardioprotective properties.
- Oxytocin may mitigate reperfusion injury and exhibit pharmacologic preconditioning activity.
- Oxytocin demonstrates beneficial effects on myocardial function in IHD models.
Conclusions:
- Oxytocin is a potential candidate for novel therapeutic strategies in ischemic heart disease.
- Further clinical studies are warranted to explore oxytocin's efficacy in managing IHD.
- Oxytocin may enhance cardioprotection, offering a new treatment modality for myocardial protection.
Abstract:
Ischemic heart disease (IHD) is among the most important and top ranked causes of death in the world, and its preventive and interventional mechanisms are actively being investigated. Preconditioning may still be beneficial in some situations such as IHD. Development of cardioprotective agents to improve myocardial function, to decrease the incidence of arrhythmias, to delay the onset of necrosis, and to limit the total extent of infarction during IHD is of great clinical importance. In order to reduce morbidity, a new treatment modality must be developed, and oxytocin may indeed be one of the candidates. There is increasing experimental evidence indicating that oxytocin may have cardioprotective effects either by decreasing the extent of reperfusion injury or by pharmacologic preconditioning activity. This review shows that in the presence of oxytocin, the cardioprotective effects may be increased to some extent. The presented board of evidence focuses on the valuable effects of oxytocin on myocardial function and candidates it for future clinical studies in the realm of ischemic heart diseases.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:26Heart Failure Drugs: Inotropic Agents
01:29Pathophysiology of Cardiac Performance
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Factors Influencing Heart Rate
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
01:27Coronary Artery Disease V: Interprofessional Care